<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28892475</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of a national enterovirus 71 vaccination program in China.</ArticleTitle><Pagination><StartPage>e0005899</StartPage><MedlinePgn>e0005899</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0005899</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0005899</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Enterovirus 71 (EV71) has caused great morbidity, mortality, and use of health service in children younger than five years in China. Vaccines against EV71 have been proved effective and safe by recent phase 3 trials and are now available in China. The purpose of this study was to evaluate the health impact and cost-effectiveness of a national EV71 vaccination program in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using Microsoft Excel, a decision model was built to calculate the net clinical and economic outcomes of EV71 vaccination compared with no EV71 vaccination in a birth cohort of 1,000,000 Chinese children followed for five years. Model parameters came from published epidemiology, clinical and cost data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the base-case, vaccination would annually avert 37,872 cases of hand, foot and mouth disease (HFMD), 2,629 herpangina cases, 72,900 outpatient visits, 6,363 admissions to hospital, 29 deaths, and 945 disability adjusted life years. The break-even price of the vaccine was $5.2/dose. When the price was less than $8.3 or $14.6/dose, the vaccination program would be highly cost-effective or cost-effective, respectively (incremental cost-effectiveness ratio less than or between one to three times China GDP per capita, respectively). In one-way sensitivity analyses, the HFMD incidence was the only influential parameter at the price of $5/dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within the price range of current routine vaccines paid by the government, a national EV71 vaccination program would be cost-saving or highly cost-effective to prevent EV71 related morbidity, mortality, and use of health service among children younger than five years in China. Policy makers should consider including EV71 vaccination as part of China's routine childhood immunization schedule.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jianwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Xi'an Children's Hospital, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Huiling</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Department of Infectious Diseases, Xi'an Children's Hospital, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Shuangsuo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3231-6531</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28892475</ArticleId><ArticleId IdType="pmc">PMC5608421</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0005899</ArticleId><ArticleId IdType="pii">PNTD-D-17-00527</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T (2010) Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol
9: 1097&#x2013;1105. doi: 10.1016/S1474-4422(10)70209-X
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong EJ, Lee JH, Kim MS, Bae GR, Jung C, et al. (2010) Molecular characterization of enteroviruses detected in Gyeong-Ju and Po-Hang provinces of Korea in 2003. Arch Virol
155: 1707&#x2013;1712. doi: 10.1007/s00705-010-0755-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-010-0755-4</ArticleId><ArticleId IdType="pubmed">20640907</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis
31: 678&#x2013;683. doi: 10.1086/314032
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PV, Thao NT, Perera D, Huu TK, Tien NT, et al. (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis
13: 1733&#x2013;1741. doi: 10.3201/eid1311.070632
</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1311.070632</ArticleId><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med
341: 929&#x2013;935. doi: 10.1056/NEJM199909233411301
</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, et al. (2014) Hand, foot, and mouth disease in China, 2008&#x2013;12: an epidemiological study. Lancet Infect Dis
14: 308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention. Epidemic information. http://www.nhfpc.gov.cn/zhuzhan/yqxx/lists.shtml.</Citation></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis
10: 778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, et al. (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
381: 2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, et al. (2014) An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med
370: 829&#x2013;837. doi: 10.1056/NEJMoa1303224
</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, et al. (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med
370: 818&#x2013;828. doi: 10.1056/NEJMoa1304923
</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, et al. (2010) Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine
28: 7731&#x2013;7736. doi: 10.1016/j.vaccine.2010.09.065
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.09.065</ArticleId><ArticleId IdType="pmc">PMC2989421</ArticleId><ArticleId IdType="pubmed">20923711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YH, Xiao GX, Guo Y, Yu SC, Ma JQ (2014) The epidemic features of the hand, foot, and mouth disease during 2008&#x2013;2011 in China. Chin J Dis Control Pre 18: 693&#x2013;697.</Citation></Reference><Reference><Citation>Chang LY, Hsia SH, Wu CT, Huang YC, Lin KL, et al. (2004) Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J 23: 327&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15071287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ (2000) An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17: 23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, et al. (1999) Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet
354: 1682&#x2013;1686. doi: 10.1016/S0140-6736(99)04434-7
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, et al. (1999) Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis
29: 184&#x2013;190. doi: 10.1086/520149
</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520149</ArticleId><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY (2007) Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics
120: e244&#x2013;252. doi: 10.1542/peds.2006-3331
</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, Li YF, Wang XH, Lu GP, Shen HG, et al. (2012) Epidemiology of hand, foot, and mouth disease in children in Shanghai 2007&#x2013;2010. Epidemiol Infect
140: 1122&#x2013;1130. doi: 10.1017/S0950268811001622
</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268811001622</ArticleId><ArticleId IdType="pubmed">21878145</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YQ, Sun LM, Zhang ZM, Deng AP, Chao B, et al. (2010) Clinical characteristics and status of health care seeking among 256 HFMD patients infected with other enterovirus. South China J Prev Med 36: 36&#x2013;38.</Citation></Reference><Reference><Citation>Wei M, Meng F, Wang S, Li J, Zhang Y, et al. (2017) 2-year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis
215:56&#x2013;63. doi: 10.1093/infdis/jiw502
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Yen C, Fang ZY, Tate JE, Jiang B, et al. (2012) Projected health impact and cost-effectiveness of rotavirus vaccination among children &lt;5 years of age in China. Vaccine
30: 6940&#x2013;6945. doi: 10.1016/j.vaccine.2012.05.084
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.05.084</ArticleId><ArticleId IdType="pubmed">22705174</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics of China. Tabulation on the 2010 Population Census of the People's Republic of China. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm.</Citation></Reference><Reference><Citation>Fox-Rushby JA, Hanson K (2001) Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 16: 326&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of the People's Republic of China. (2010) Guideline for diagnosis and treatment of hand, foot and mouth disease (2010 edition). Int J Respir 30: 1473&#x2013;1475.</Citation></Reference><Reference><Citation>Xu W, Liu CF, Yan L, Li JJ, Wang LJ, et al. (2012) Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J
9: 8
doi: 10.1186/1743-422X-9-8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-8</ArticleId><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. The global burden of disease: 2004 update. Geneva: WHO; 2004.</Citation></Reference><Reference><Citation>Gan ZK, Jin H, Li JX, Yao XJ, Zhou Y, et al. (2015) Disease burden of enterovirus 71 in rural central China: A community-based survey. Hum Vaccin Immunother
11: 2400&#x2013;2405. doi: 10.1080/21645515.2015.1059980
</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1059980</ArticleId><ArticleId IdType="pmc">PMC4635911</ArticleId><ArticleId IdType="pubmed">26158689</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T (2013) Research on economic burden of disease and its determinants of hand, foot and mouth disease patient in Shangdong province. Thesis of Shandong University.</Citation></Reference><Reference><Citation>Ma TZ (2012) Study on epidemiology and economic burden of hand-foot-mouth disease in Kuancheng District of Changchun City during 2010&#x2013;2011. Thesis of Jilin University.</Citation></Reference><Reference><Citation>Qin YJ (2009) Study on epidemiology and economic burden of hand-foot-mouth disease in Yantai City. Thesis of Shandong University.</Citation></Reference><Reference><Citation>Wang ZL, Xia AM, Li YF, Su HL, Zhan LW, et al. (2016) Socioeconomic burden of hand, foot and mouth disease in children in Shanghai, China. Epidemiol Infect
144: 138&#x2013;143. doi: 10.1017/S0950268815001569
</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268815001569</ArticleId><ArticleId IdType="pmc">PMC9507314</ArticleId><ArticleId IdType="pubmed">26159305</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu DZ, Wang XD, Li Q, Deng CL, Liu JJ, et al. (2013) Investigation on the financial burden of HFMD of the under-5-year-old children in Hainan Reclamation area. Hainan Yi Xue 24: 3723&#x2013;3726.</Citation></Reference><Reference><Citation>Yuan GP, Li MZ, Xiang LH (2013) Study of economic burden of HFMD in Baoshan District of Shanghai City in 2011. Shanghai Yu Fang Yi Xue 25: 577&#x2013;580.</Citation></Reference><Reference><Citation>Yin J, Ji Z, Liang P, Wu Q, Cui F, et al. (2015) The doses of 10mug should replace the doses of 5mug in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine
33: 3731&#x2013;3738. doi: 10.1016/j.vaccine.2015.05.082
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.082</ArticleId><ArticleId IdType="pubmed">26057138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X (2003) Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ 81: 334&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572455</ArticleId><ArticleId IdType="pubmed">12856051</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics of China. Consumer Price Index. www.stats.gov.cn.</Citation></Reference><Reference><Citation>Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849754</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Cost-effectiveness threshold values. http://www.who.int/choice/costs/en/.</Citation></Reference><Reference><Citation>National Health and Family Planning Commission of the People's Republic of China. China Public Health Statistical Yearbook 2011. http://www.moh.gov.cn/zhuzhan/index.shtml.</Citation></Reference><Reference><Citation>Huang MC, Wang SM, Hsu YW, Lin HC, Chi CY, et al. (2006) Long-term cognitive and motor deficits after enterovirus 71 brainstem encephalitis in children. Pediatrics
118: e1785&#x2013;1788. doi: 10.1542/peds.2006-1547
</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-1547</ArticleId><ArticleId IdType="pubmed">17116698</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Ma YX, Zhang CB, Chen YP, Ye XJ, et al. (2012) Neurologic complications in children with enterovirus 71-infected hand-foot-mouth disease: clinical features, MRI findings and follow-up study. Zhonghua Yi Xue Za Zhi 92: 1742&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">22944180</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva, Switzerland: World Health Organization, 2011. 
http://www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf</Citation></Reference><Reference><Citation>Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, et al. (2012) Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis
6: e1737
doi: 10.1371/journal.pntd.0001737
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001737</ArticleId><ArticleId IdType="pmc">PMC3429393</ArticleId><ArticleId IdType="pubmed">22953003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine
29: 4829&#x2013;4838. doi: 10.1016/j.vaccine.2011.04.070
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.070</ArticleId><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine
29: 6269&#x2013;6275. doi: 10.1016/j.vaccine.2011.06.044
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Cheng T, Zhu F, Li J, Wang Y, et al. (2013) The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS One
8: e79599
doi: 10.1371/journal.pone.0079599
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CW, Lee YP, Wang YF, Yu CK (2011) Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine
29: 2772&#x2013;2776. doi: 10.1016/j.vaccine.2011.01.094
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.094</ArticleId><ArticleId IdType="pubmed">21315698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>